Intravenous colistin for multidrug-resistant gram-negative infections in critically ill pediatric patients

Pediatric Critical Care Medicine

Volumn 14, Issue 6, 2013, Pages

  Kapoor, Kapil ^a   Jajoo, Mamta ^a   Dublish, Swati ^a   Dabas, Vikas ^a   Gupta, Shalu ^a   Manchanda, Vikas ^a  

^a MAULANA AZAD MEDICAL COLLEGE   (India)

Author keywords

Acinetobacter baumannii; Children; Colistin; Klebsiella pneumoniae; Nosocomial infection; Pseudomonas aeruginosa

Indexed keywords

AMINOGLYCOSIDE; AMPHOTERICIN B; CEFTRIAXONE; COLISTIN; FLUCONAZOLE; MEROPENEM; MIDAZOLAM; MORPHINE; PANCURONIUM; PIPERACILLIN; VANCOMYCIN;

ACINETOBACTER BAUMANNII; AIR CONDITIONING; ARTICLE; CRITICALLY ILL PATIENT; DISEASE SEVERITY; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; HUMAN; KLEBSIELLA PNEUMONIAE; MULTIPLE ORGAN FAILURE; NEPHROTOXICITY; NEUROMUSCULAR BLOCKING; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; SAMPLE SIZE; SEPSIS;

EID: 84880795840     PISSN: 15297535     EISSN: 19473893     Source Type: Journal    
DOI: 10.1097/PCC.0b013e31828a740f     Document Type: Article

References (25)

1. Apisarnthanarak A, Holzmann-Pazgal G, Hamvas A, et al: Ventilatorassociated pneumonia in extremely preterm neonates in a neonatal intensive care unit: Characteristics, risk factors, and outcomes. Pediatrics 2003; 112(6 Pt 1): 1283-1289
2. Lakshmi KS, Jayashree M, Singhi S, et al: Study of nosocomial primary bloodstream infections in a pediatric intensive care unit. J Trop Pediatr 2007; 53: 87-92
3. Catchpole CR, Andrews JM, Brenwald N, et al: A reassessment of the in-vitro activity of colistin sulphomethate sodium. J Antimicrob Chemother 1997; 39: 255-260
4. Levin AS, Barone AA, Penço J, et al: Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999; 28: 1008-1011
5. Evans ME, Feola DJ, Rapp RP: Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother 1999; 33: 960-967
6. Hancock RE, Chapple DS: Peptide antibiotics. Antimicrob Agents Chemother 1999; 43: 1317-1323
7. Garnacho-Montero J, Ortiz-Leyba C, Jiménez-Jiménez FJ, et al: Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: A comparison with imipenem-susceptible VAP. Clin Infect Dis 2003; 36: 1111-1118
8. Koch-Weser J, Sidel VW, Federman EB, et al: Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 1970; 72: 857-868
9. Littlewood JM, Koch C, Lambert PA, et al: A ten year review of colomycin. Respir Med 2000; 94: 632-640
10. Falagas ME, Vouloumanou EK, Rafailidis PI: Systemic colistin use in children without cystic fibrosis: A systematic review of the literature. Int J Antimicrob Agents 2009; 33: 503.e1-503.e13
11. Iosifidis E, Antachopoulos C, Ioannidou M, et al: Colistin administration to pediatric and neonatal patients. Eur J Pediatr 2010; 169: 867-874
12. Horan TC, Andrus M, Dudeck MA: CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008; 36: 309-332
13. Falagas ME, Karageorgopoulos DE: Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram-negative bacilli: Need for international harmonization in terminology. Clin Infect Dis 2008; 46: 1121-1122
14. Celebi S, Hacimustafaoglu M, Koksal N, et al: Colistimethate sodium therapy for multidrug-resistant isolates in pediatric patients. Pediatr Int 2010; 52: 410-414
15. Schwartz GJ, Brion LP, Spitzer A: The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 1987; 34: 571-590
16. Clinical Laboratory Standards Institute: Performance standards for antimicrobial susceptibility testing: Sixteenth Informational Supplement. 2006; M100-S16
17. Joint Formulary Committee 2002-2003: British National Formulary. London, British Medical Association and Royal Pharmaceutical Society of Great Britain, 2003, p 281
18. Gupta S, Govil D, Kakar PN, et al: Colistin and polymyxin B: A reemergence. Indian J Crit Care Med 2009; 13: 49-53
19. Falagas ME, Kasiakou SK, Kofteridis DP, et al: Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) gram-negative bacteria. Eur J Clin Microbiol Infect Dis 2006; 25: 596-599
20. Rosanova M, Epelbaum C, Noman A, et al: Use of colistin in a pediatric burn unit in Argentina. J Burn Care Res 2009; 30: 612-615
21. Falagas ME, Sideri G, Vouloumanou EK, et al: Intravenous colistimethate (colistin) use in critically ill children without cystic fibrosis. Pediatr Infect Dis J 2009; 28: 123-127
22. Wolinsky E, Hines JD: Neurotoxic and nephrotoxic effects of colistin patients with renal disease. N Engl J Med 1962; 266: 759-762
23. Michalopoulos AS, Tsiodras S, Rellos K, et al: Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gramnegative bacteria: The renaissance of an old antibiotic. Clin Microbiol Infect 2005; 11: 115-121
24. Clermont G, Acker CG, Angus DC, et al: Renal failure in the ICU: Comparison of the impact of acute renal failure and end-stage renal disease on ICU outcomes. Kidney Int 2002; 62: 986-996
25. Li J, Nation RL, Milne RW, et al: Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents 2005; 25: 11-25